New CEO and Her Background
Bavarian Nordic said Thursday that Tarja Stenvall will take the helm on Oct. 15. The company described her as a former Sanofi executive with decades in big pharma, including roles at AstraZeneca Plc and Pfizer Inc. She steps in as the company refreshes its leadership bench.
Why Leadership Is Changing
Tarja Stenvall takes over from Paul Chaplin, whose planned exit had been disclosed earlier this year. In March, Bavarian Nordic said Chaplin would exit by the end of 2024 or when a successor was appointed, setting the stage for today's handoff.
What Triggered The Shakeup
Leadership changes remind investors to review their portfolio's resilience and long term goals. Join Briefs Finance CEO Jaspreet Singh on September 29th for a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, where he shows how we're spotting investment opportunities as the dollar falls. Save your spot.
Where The Company Stands Now
Bavarian Nordic is widely known for its smallpox vaccine, which is also used to protect against mpox. The company secured several large government supply deals during the 2022 mpox outbreak and again in 2024. Not everything has gone its way, though: its respiratory syncytial virus program suffered a major failure in 2023. For everyday investors, the picture is a mix of a new leader stepping in, a proven product with episodic demand, and a reminder that pipeline swings can move results.
Staying steady through company transitions helps protect and grow your hard earned savings. Our CEO Jaspreet Singh is hosting a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, on September 29th. Sign up free to join him live.
